Investor Presentation

2022e revenue splits (directional) Consumables, biopharma development and mAb applications were the largest contributors CONSUMABLES/EQUIPMENT % of Total Revenue 25% R REPLIGEN 75% Equipment Consumables BIOPHARMA/CDMO/INTEGRATORS % of Total Revenue 17% 4% 29% 49% Biopharma Developers CDMOS Integrators Other 2022e total revenue reflects 2022 financial results as of Feb. 22, 2023. BIOLOGIC TYPE 18% (COVID) 14% (C&GT) $141M TOTAL: $802M $115M 68% (mAbs) $546M 6

View entire presentation